Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.
Individuals with poor and intermediate versus good health more likely to continue insulin use
Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.
Findings seen among patients with heart failure, reduced ejection fraction, irrespective of diabetes
Risk lower for heart failure, but not major CV events, compared with new users of DPP4 inhibitors.
Linagliptin compared with glimepiride for risk for major cardiovascular events in T2DM with elevated CV risk
Rybelsus is the first glucagon-like peptide (GLP-1) available in a tablet formulation that is approved for once daily use
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
Researchers investigated the effects of canagliflozin on serum urate levels and gout in patients with type 2 diabetes.
The benefits of early diagnosis of chronic kidney disease (CKD) are significant, as patients in whom CKD is diagnosed in the early stages have the chance to make lifestyle changes, learn how to manage their disease, and extend their lives while avoiding or postponing the need for dialysis or transplant.
